Walgreens Q2 2016 Earnings Review: Acquisition Synergies To Boost Margins Going Forward
Walgreens (NASDAQ:WBA), one of the largest pharmacies in the US released its Q2 2016 earnings on April 5th. (Fiscal years end with August.) The company reported a strong quarter driven by the acquisition of Alliance Boots and growth in Medicare Part D prescriptions . Following is a brief look at the numbers and trends that drove WBA’s performance in the second quarter.
- A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly’s Q1
- What Should You Do With Danaher Stock At $250 After Q1 Beat?
- Will A Macau Recovery Drive MGM Stock Higher Following Q1 Results?
- Lockheed Martin Stock Will Likely Remain In Focus After A Stellar Q1
- Up 17% YTD, What To Expect From eBay Q1 Results?
- Rising 21% This Year, What Lies Ahead For Exxon Stock Following Q1 Earnings?
Factors That Will Drive Growth Going Forward
- Rite Aid’s acquisition (expected completion in second half of 2016) will add to the Retail Pharmacy USA business and help grow WBA’s market share
- High Comparable store sales will continue to positively impact revenues driven by the growing Medicare Part D priscriptions
- International Pharmacy and Pharmaceutical Wholesale business will continue to grow
- Higher synergy benefits expected from AmerisouceBergen and refinancing Alliance Boots Indebtedness at a lower cost
Offsetting Factor
- Generic Drugs will continue to adversely impact revenues
Notes:
View Interactive Institutional Research (Powered by Trefis):
Global Large Cap | U.S. Mid & Small Cap | European Large & Mid Cap